PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion

BACKGROUND: The 1st interim analysis of the CATNON trial showed benefit from adjuvant (adj) temozolomide (TMZ) on overall survival (OS) but remained inconclusive about concurrent (conc) TMZ. A 2nd interim analysis was planned after 356 events. MATERIAL AND METHODS: The 2x2 factorial design phase III...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: van den Bent, M J, Erridge, S, Vogelbaum, M A, Nowak, A K, Sanson, M, Brandes, A A, Wick, W, Clement, P M, Baurain, J F, Mason, W, Wheeler, H, Weller, M, Aldape, K, Wesseling, P, Kros, J M, Tesileanu, C M S, Golfinopoulos, V, Gorlia, T, Baumert, B G, French, P J
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Oral Presentations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6794941/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados